Tuberculosis in children: New diagnostic blood tests

F Kakkar, UD Allen, D Ling, M Pai, IC Kitai; Canadian Paediatric Society; Infectious Diseases and Immunization Committee

The interferon-gamma-release assays were developed to overcome the pitfalls and logistic difficulties of the tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection (LTBI). These blood tests measure the in vitro production of interferon-gamma by sensitized lymphocytes in response to Mycobacterium tuberculosis-specific antigens. Two interferon-gamma-release assays are registered for use in Canada: the QuantiFERON-TB Gold In-Tube assay (Cellestis Inc., Australia) and the T.SPOT–TB test (Oxford Immunotec, United Kingdom). Evaluation of these tests has been hampered by the lack of a gold standard for LTBI, and limited paediatric data on their use. It appears that they are more specific than the TST, and may be useful for evaluating TST-positive patients at low risk of true LTBI. Moreover, they may add sensitivity if used in addition to the TST in immunocompromised patients, very young children and close contacts of infectious adults. A summary of these tests, their limitations and their application to clinical paediatric practice are described.

Key Words: Diagnosis; Interferon-gamma-release assay; Paediatrics; Tuberculosis

For centuries, paediatric tuberculosis (TB) has been a challenge for physicians to diagnose and treat (1-3). Unlike TB in adults, paediatric TB often presents with non-specific signs and symptoms. Paediatric TB is usually paucibacillary, and culture confirmation is difficult and not always possible (4-6). At the same time, the diagnosis of latent TB infection (LTBI), while extremely important in paediatrics, can be challenging due to the limitations in the sensitivity and specificity of the only available screening test to date – the tuberculin skin test (TST) (7). The test is supported by longitudinal data showing a much higher risk of TB disease in TST-positive individuals who have been previously vaccinated with Bacillus Calmette-Guérin (BCG) or infected with environmental nontuberculous mycobacteria (NTM). The test is further hampered by poor standardization, inter- and intra-observer variability, and the need for a return visit for interpretation.

ADVANCES IN TB DIAGNOSIS: THE INTERFERON-GAMMA-RELEASE ASSAYS

These tests measure the in vitro production of interferon-gamma by sensitized lymphocytes in response to Mycobacterium tuberculosis-specific antigens. Two interferon-gamma-release assays are registered for use in Canada: the QuantiFERON-TB Gold In-Tube assay (Cellestis Inc., Australia) and the T.SPOT–TB test (Oxford Immunotec, United Kingdom). Evaluation of these tests has been hampered by the lack of a gold standard for LTBI, and limited paediatric data on their use. It appears that they are more specific than the TST, and may be useful for evaluating TST-positive patients at low risk of true LTBI. Moreover, they may add sensitivity if used in addition to the TST in immunocompromised patients, very young children and close contacts of infectious adults. A summary of these tests, their limitations and their application to clinical paediatric practice are described.

Key Words: Diagnosis; Interferon-gamma-release assay; Paediatrics; Tuberculosis

Les tests de détection de l’interféron gamma ont été mis au point pour vaincre les écueils et les problèmes logistiques liés à l’intradermoreréaction à la tuberculine (IDR) afin de diagnostiquer la tuberculose-infection latente (TBIL). Ces analyses sanguines mesurent la production in vitro d’interféron gamma par des lymphocytes sensibilisés en réponse aux antigènes spécifiques de Mycobacterium tuberculosis. Deux tests de détection de l’interféron gamma sont homologués au Canada : le test QuantiFERON-TB Gold In-Tube (Cellestis Inc., Australie) et le test T.SPOT–TB (Oxford Immunotec, Royaume-Uni). Leur évaluation a été gênée par l’absence de norme de référence de la TBIL et par le peu de données pédiatriques quant à leur usage. Il semble qu’ils soient plus précis que l’IDR et qu’ils puissent être utiles pour évaluer les patients positifs à l’IDR peu vulnérables à une véritable TBIL. De plus, ils pourraient être plus sensibles s’ils s’ajoutent à l’IDR chez les patients immunocompromis, les très jeunes enfants et les contacts étroits d’adultes infectés. Un sommaire de ces tests, leurs limites et leur application à la pratique clinique en pédiatrie sont présentés.
tuberculosis-specific antigens. The genes encoding these antigens are present in \( M. \) \( \text{tuberculosis} \), but are not found in any BCG strain or in several of environmental NTM strains (12-14). Therefore, these tests are substantially more specific (leading to fewer false positives) than the TST. They are also less subjective with respect to interpretation, have the potential for rapid turnaround time, and require only a single visit to complete the testing process. Two commercial interferon-gamma-release assays (IGRAs) using these \( M. \) \( \text{tuberculosis} \)-specific antigens are now currently registered for use in Canada – the QuantiFERON-TB Gold In-Tube assay (QFT-G-IT; Cellestis Inc, Australia) and the T.SPOT–TB test (Oxford Immunotec, United Kingdom).

Brief descriptions of the tests are presented in Table 2. They are not yet widely available at most centres or reference laboratories in Canada. Both tests are also approved by the United States Food and Drug Administration (15,16). The ELISpot, while similar to the T.SPOT, is an in-house assay not available for commercial use, although it is frequently referenced in studies of the IGRAs.

**ROLE OF THE IGRAS IN CHILDREN: WHEN SHOULD THEY BE USED?**
While the IGRAs have been well studied in adults and reviewed elsewhere (17), data regarding their use in children are much more limited. Current recommendations for their use...
in children are best understood in the context of this limited available information. In summary, in low TB incidence settings, there is general support that the tests are more specific and correlate better with gradients of exposure to infectious source cases than the TST (18-21). However, evaluation of this is hampered by the lack of a gold standard test for the diagnosis of LTBI, and the lack of longitudinal data to validate the predictive value of the IGRAs compared with the TST. Overall agreement between the TST and the IGRA in the diagnosis of LTBI in children appears to be between 55% and 95% (18-20,22,23), and varies depending on age and history of previous BCG vaccination (24). The majority of discordant results are “TST+/IGRA”, and there is concern that the IGRAs may not be as sensitive as the TST for the diagnosis of LTBI in very young and immunocompromised children, and whether the initial infection was remote (24,25). The 2009 American Academy of Pediatrics Red Book recommendations on TB states that “IGRAs cannot be recommended routinely for use in children younger than 5 years of age or for immunocompromised children of any age because of a lack of published data about their utility with these groups (26)”. While there are limited data to suggest that the IGRAs, especially the T.SPOT, may have increased sensitivity over the TST in immunocompromised populations, this again has not been well studied in children and is based on a limited number of adult studies (17). However, the T.SPOT is more difficult to perform, more expensive and requires larger volumes of blood than the QFT-G-IT.

There is also variable sensitivity reported in children with active tuberculosis disease, ranging from 50% to 92% for QFT-G-IT, 81% to 93% for ELISpot, and 40% to 83% for T.SPOT-TB (18-20,27-29). The wide range in reported sensitivity appears to reflect the different performances of these tests across different ages and in different settings (endemic versus nonendemic). In very young children with TB, the test may have limited sensitivity, but there are notable cases on record in which the TST is negative and the IGRA is positive (29). The combination of the two tests may, therefore, increase sensitivity for the diagnosis of TB, both latent and active, in situations in which the TST may be unreliable such as in active and or disseminated TB disease, and in latent disease of very young infants and immunocompromised patients.

Acknowledging these limitations, recommendations on IGRAs for latent TB infection were made by the Canadian Tuberculosis Committee in 2007 and updated in 2008 and 2010 (30-32). Members of the Infectious Diseases and Immunization Committee of the Canadian Paediatric Society reviewed and agreed with the 2008 updated guidelines, which include specific recommendations for the use of the IGRAs for children, as described below.

**CANADIAN TB COMMITTEE RECOMMENDATIONS ON THE USE OF IGRAS FOR CHILDREN:**

- The IGRAs may be used as a supplementary diagnostic aid in combination with the TST to help support the diagnosis of active TB.
- The IGRA may be used in the setting of contact investigation to confirm a positive TST in contacts who, on the basis of an assessment of the duration and degree of contact with an active infectious case, are believed to have a low pretest probability of recently acquired LTBI, and who have no other high or increased risk factors for progression to active disease if infected.
- The IGRA may be performed in a TST-positive, immunocompetent child with relatively low risk of being infected with TB, and of progressing to active disease if infected. Persons with a positive IGRA result may be considered for treatment of LTBI.
- The IGRA may be useful to confirm diagnosis of LTBI for treatment purposes. Any decision not to offer chemoprophylaxis on the basis of a negative IGRA may be useful to confirm diagnosis of LTBI for treatment purposes. Any decision not to offer chemoprophylaxis on the basis of a negative IGRA must be made in consultation with a TB specialist.
- Routine or mass screening of all immigrant children for LTBI, with either TST or IGRA, is not recommended. However, targeted screening for LTBI after arrival in Canada is recommended for foreign-born children and travellers with risk factors for reactivation of LTBI.

Imigrant children who should be targeted for LTBI screening include those younger than 15 years of age who have lived in a country with high TB incidence and have immigrated within the past two years, and children with risk factors for progression to disease, as outlined in Table 3.


**REFERENCES**


**TABLE 3**

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Estimated risk of TB relative to persons with no known risk factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk</td>
<td></td>
</tr>
<tr>
<td>AIDS</td>
<td>110–170</td>
</tr>
<tr>
<td>HIV infection</td>
<td>50–110</td>
</tr>
<tr>
<td>Transplantation (related to immunosuppressive therapy)</td>
<td>20–74</td>
</tr>
<tr>
<td>Silicosis</td>
<td>30</td>
</tr>
<tr>
<td>Chronic renal failure requiring hemodialysis</td>
<td>10–15</td>
</tr>
<tr>
<td>Carcinoma of head and neck</td>
<td>16</td>
</tr>
<tr>
<td>Recent TB infection (two years or less)</td>
<td>15</td>
</tr>
<tr>
<td>Abnormal chest x-ray – fibronodular disease</td>
<td>16–19</td>
</tr>
<tr>
<td>Increased risk</td>
<td></td>
</tr>
<tr>
<td>Treatment with glucocorticoids</td>
<td>4.9</td>
</tr>
<tr>
<td>Tumour necrosis factor-alpha inhibitors</td>
<td>1.5–4</td>
</tr>
<tr>
<td>Diabetes mellitus (all types)</td>
<td>2.0–3.6</td>
</tr>
<tr>
<td>Underweight (90% or lower of ideal body weight; for most persons, this corresponds to a body mass index of 20 kg/m² or lower)</td>
<td>2–3</td>
</tr>
<tr>
<td>Young age when infected (zero to four years of age)</td>
<td>2.2–5.0</td>
</tr>
<tr>
<td>Cigarette smoker (one pack/day)</td>
<td>2–3</td>
</tr>
<tr>
<td>Abnormal chest x-ray – granuloma</td>
<td>2</td>
</tr>
<tr>
<td>Low risk</td>
<td></td>
</tr>
<tr>
<td>Infected person, no known risk factor, normal chest x-ray (low risk reactor)</td>
<td>1</td>
</tr>
</tbody>
</table>

The IGRAs can be used, in addition to the TST, to diagnose LTBI in an immunocompromised patient. In an immunocompromised child, the TST should still be the initial test used to detect LTBI. If the TST is positive, the child should be considered to have LTBI. However, given the known problem with false-negative TST results in immunocompromised populations, a physician still concerned about the possibility of LTBI in an immunocompromised child with a negative initial TST result may perform an IGRA test.

ACKNOWLEDGEMENTS: The principal authors thank Daphne Ling and Madhukar Pai for their assistance during the development of this document.


INFECTIOUS DISEASES AND IMMUNIZATION COMMITTEE (2009-2010)

Members: Drs Robert Bortolussi, IWK Health Centre, Halifax, Nova Scotia (Chair); Jane Finlay, Richmond, British Columbia; Jane C McDonald, The Montreal Children’s Hospital, Montreal, Quebec; Heather Onyett, Kingston General Hospital, Kingston, Ontario; Joan L Robinson, Edmonton, Alberta; Élisabeth Rousseau-Harsany, Sainte-Justine UHC, Montreal, Quebec (Board Representative)

Liaisons: Drs Upton D Allen, The Hospital for Sick Children, Toronto, Ontario (Canadian Pediatric AIDS Research Group); Charles PS Hui, Children’s Hospital of Eastern Ontario, Ottawa, Ontario (CPS Liaison to Health Canada, Committee to Advise on Tropical Medicine and Travel); Nicole Le Saux, Children’s Hospital of Eastern Ontario, Ottawa, Ontario (Immunization Program, ACTive); Larry Pickering, Elk Grove, Illinois, USA (American Academy of Pediatrics); Marina I Salvadori, Children’s Hospital of Western Ontario, Ottawa, Ontario (CPS Liaison to Health Canada, National Advisory Committee on Immunization)

Consultants: Drs James Kellner, Calgary, Alberta; Ian C Kitai, The Hospital for Sick Children, Toronto, Ontario, Noni E MacDonald, IWK Health Centre, Halifax, Nova Scotia; Dorothy L Moore, The Montreal Children’s Hospital, Montreal, Quebec

Principal authors: Ms Fatima Kakkar, Drs Upton Allen and Ian C Kitai, The Hospital for Sick Children, Toronto, Ontario

The recommendations in this statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. All Canadian Paediatric Society position statements and practice points are reviewed, revised or retired as needed on a regular basis. Please consult the “Position Statements” section of the CPS website (www.cps.ca/english/publications/statementsindex.htm) for the most current version. This article also appears in the October 2010 issue of Paediatrics & Child Health.